» Articles » PMID: 36343842

Structural Basis for Cell Type Specific DNA Binding of C/EBPβ: The Case of Cell Cycle Inhibitor P15INK4b Promoter

Overview
Journal J Struct Biol
Date 2022 Nov 7
PMID 36343842
Authors
Affiliations
Soon will be listed here.
Abstract

C/EBPβ is a key regulator of numerous cellular processes, but it can also contribute to tumorigenesis and viral diseases. It binds to specific DNA sequences (C/EBP sites) and interacts with other transcription factors to control expression of multiple eukaryotic genes in a tissue and cell-type dependent manner. A body of evidence has established that cell-type-specific regulatory information is contained in the local DNA sequence of the binding motif. In human epithelial cells, C/EBPβ is an essential cofactor for TGFβ signaling in the case of Smad2/3/4 and FoxO-dependent induction of the cell cycle inhibitor, p15INK4b. In the TGFβ-responsive region 2 of the p15INK4b promoter, the Smad binding site is flanked by a C/EBP site, CTTAA•GAAAG, which differs from the canonical, palindromic ATTGC•GCAAT motif. The X-ray crystal structure of C/EBPβ bound to the p15INK4b promoter fragment shows how GCGC-to-AAGA substitution generates changes in the intermolecular interactions in the protein-DNA interface that enhances C/EBPβ binding specificity, limits possible epigenetic regulation of the promoter, and generates a DNA element with a unique pattern of methyl groups in the major groove. Significantly, CT/GA dinucleotides located at the 5'ends of the double stranded element maintain local narrowing of the DNA minor groove width that is necessary for DNA recognition. Our results suggest that C/EBPβ would accept all forms of modified cytosine in the context of the CpT site. This contrasts with the effect on the consensus motif, where C/EBPβ binding is modestly increased by cytosine methylation, but substantially decreased by hydroxymethylation.

Citing Articles

Germline variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase ().

Zhang T, Ambrodji A, Huang H, Bouchonville K, Etheridge A, Schmidt R Elife. 2024; 13.

PMID: 38686795 PMC: 11060711. DOI: 10.7554/eLife.94075.


Germline variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase ().

Zhang T, Ambrodji A, Huang H, Bouchonville K, Etheridge A, Schmidt R bioRxiv. 2023; .

PMID: 37961517 PMC: 10635067. DOI: 10.1101/2023.11.01.565230.

References
1.
Gowher H, Jeltsch A . Enzymatic properties of recombinant Dnmt3a DNA methyltransferase from mouse: the enzyme modifies DNA in a non-processive manner and also methylates non-CpG [correction of non-CpA] sites. J Mol Biol. 2001; 309(5):1201-8. DOI: 10.1006/jmbi.2001.4710. View

2.
Adams R . Eukaryotic DNA methyltransferases--structure and function. Bioessays. 1995; 17(2):139-45. DOI: 10.1002/bies.950170209. View

3.
Bartlett A, OMalley R, Huang S, Galli M, Nery J, Gallavotti A . Mapping genome-wide transcription-factor binding sites using DAP-seq. Nat Protoc. 2017; 12(8):1659-1672. PMC: 5576341. DOI: 10.1038/nprot.2017.055. View

4.
Zhou T, Yang L, Lu Y, Dror I, Dantas Machado A, Ghane T . DNAshape: a method for the high-throughput prediction of DNA structural features on a genomic scale. Nucleic Acids Res. 2013; 41(Web Server issue):W56-62. PMC: 3692085. DOI: 10.1093/nar/gkt437. View

5.
Osada S, Yamamoto H, Nishihara T, Imagawa M . DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family. J Biol Chem. 1996; 271(7):3891-6. DOI: 10.1074/jbc.271.7.3891. View